Global Consumer Healthcare Market

Market Insights
The Consumer Healthcare market was valued at USD 325,251.1 Million in 2020, and it is expected to reach a value of USD 486,125.2 Million by 2027, at a CAGR of 6.1% over the forecast period (2021 - 2027).

High demand for self-medication, rising healthcare expenditures, an aging population that is more susceptible to disease, deterioration in mental health, and a move from pharmaceutical prescription to OTC goods are the primary drivers driving the rise of the consumer healthcare industry.

Read more about :

Segmental Analysis
By Over-the-counter (OTC) the market is segmented into analgesics, cold, cough & flu products, weight loss products, gastrointestinal products, skin products, mineral, and vitamin supplements, sleeping aids, ophthalmic products, others. By Sports Nutrition the market is segmented into sports supplements, vitamins, minerals, amino acids, probiotics, omega -3 fatty acids, carbohydrates. By vitamins and dietary supplements, the market is segmented into vitamins, botanicals, minerals, proteins & amino acids, omega fatty acids, others. By weight management and wellbeing, the market is segmented into meals, beverages, supplements. By herbal/traditional products the market is segmented into pharmaceuticals, food & beverages, personal care. By allergy care the market is segmented into nasal spray, antihistamine medication, eye drops & paediatric. Based on region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Get free sample report copy at :

Top Players Company Profiles
• Johnson & Johnson (US)
• GlaxoSmithKline (UK)
• Pfizer Inc. (US)
• Reckitt Benckiser (RB) Group PLC (UK)
• Glenmark Pharmaceuticals Ltd. (India)
• Bayer (Germany)
• Procter & Gamble (P&G) (US)
• Sanofi (France)
• Herbalife Ltd (US)
• Amway (US)
• The Nature’s Bounty Co (US)
Recent Developments
• In February 2022, GlaxoSmithKline plc (GSK) revealed the name of the new business that will emerge from GSK's proposed demerger of Consumer Healthcare in mid-2022, Haleon.
• In February 2022, Ipsen engaged in a divestment agreement with Mayoly Spindler, a French pharmaceutical company, in which Ipsen decided to sell its global consumer health portfolio.
• In January 2022, GSK strategized to sell its consumer health unit to Unilever and Pfizer as consumer health joint venture. However, Unilever will not increase its bid for the GSK-Pfizer consumer health joint venture above 50 billion pounds (USD68 billion). With Unilever's exit, GSK is back to its original goal for a spinoff by mid-2022.